Provided by Tiger Trade Technology Pte. Ltd.

Artelo Biosciences, Inc.

3.99
-1.3514-25.31%
Volume:196.55K
Turnover:805.33K
Market Cap:2.18M
PE:-0.04
High:4.90
Open:4.90
Low:3.74
Close:5.34
52wk High:179.19
52wk Low:3.74
Shares:547.78K
Float Shares:547.42K
Volume Ratio:6.27
T/O Rate:35.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-102.4151
EPS(LYR):-337.9329
ROE:-705.71%
ROA:-127.92%
PB:0.44
PE(LYR):-0.01

Loading ...

Artelo Biosciences Q2 EPS USD -0.89

THOMSON REUTERS
·
Aug 13

Press Release: Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

Dow Jones
·
Aug 13

Artelo Biosciences Q2 FY26 Net Loss Narrows 24.65% to USD 2.43 Million

Reuters
·
Aug 13

Artelo Biosciences Doses First Patient in Phase 2 Glaucoma Trial of Art27.13

Reuters
·
Aug 10

Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating Art27.13 for Treatment of Glaucoma

THOMSON REUTERS
·
Aug 10

Artelo Biosciences - Initial Dream Study Results Anticipated in Q4 2026

THOMSON REUTERS
·
Aug 10

South Korea's Stock Market Now Mirrors Nasdaq, Raising Diversification Fears Among Investors

Deep News
·
Jul 28

Artelo Analysis Finds Low-dose OTC CBD Products Miss Therapeutic Efficacy Across 50-plus Studies

Reuters
·
Jul 22

Artelo Biosciences announces new ART26.12 data

TIPRANKS
·
Jul 16

Artelo Says Preclinical Osteoarthritis Study Shows Art26.12 Matches Naproxen Pain Relief with Less Gastric Damage

Reuters
·
Jul 16

Artelo Biosciences - to Begin Clinical Multiple Ascending Dose Study of Art26.12 in Q4

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting Art26.12 as a Potential First-in-class New Therapy for Chronic Pain Conditions

THOMSON REUTERS
·
Jul 16

Artelo Biosciences - Art26.12 Shows Efficacy Comparable to Naproxen in Nonclinical Osteoarthritis Study

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Annual Shareholder Meeting

Reuters
·
Jul 14

Artelo Biosciences Reports Positive Preclinical Data for Art27.13 in Paclitaxel-induced Peripheral Neuropathy Model

Reuters
·
Jul 13

Artelo Biosciences - Interim Results Show Improved Body Weight, Lean Mass, Activity, and Safety up to 1300 Μg/day

THOMSON REUTERS
·
Jul 13

Artelo Biosciences - Art27.13 Reduces Neuropathic Pain Behaviors in Paclitaxel-treated Animals

THOMSON REUTERS
·
Jul 13

SK Hynix's Landmark Nasdaq Debut Bets on AI Reshaping Memory Chip Industry's Boom-Bust Cycle

Deep News
·
Jul 11

SK hynix's $26.5 Billion Nasdaq Debut: A Test for Overcoming the 'Korea Discount'

Stock News
·
Jul 10

Artelo Biosciences presents preclinical pain data for ART26.12

TIPRANKS
·
Jul 01